MetaCap

Bolt Biotherapeutics (BOLT) vs Tvardi Therapeutics (TVRD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tvardi Therapeutics is the larger company by market cap ($13.2 million vs $12.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLT+36.39%TVRD-10.06%
+89%+28%-33%
Oct 7, 20261 yearNov 20, 2026
BOLT+19.46%TVRD-3.95%
+65%+19%-27%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLT versus TVRD key metrics
MetricBOLTTVRD
Share price$4.91$0.9893
Market cap$12.80M$13.22M
1-day change-2.96%+4.57%
YTD return—-76.99%
1-year return—-74.76%
5-year return—-99.79%
EPS (TTM)$-14.00$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.70M—
Revenue growth (YoY)+0.07%—
Net income (latest FY)$-33.38M$-18.21M
Operating margin-469.30%—
Net margin-433.74%—
52-week high$7.78$5.69
52-week low$3.10$0.773
Distance from 52-week high-36.89%-82.61%
Analyst consensusnonebuy
Avg. price target upside+490.63%+835.00%
Average volume257.43K235.95K
Shares outstanding2.61M13.36M
Employees2312
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Tvardi Therapeutics

TVRD stock →

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

BOLT vs TVRD FAQ

Which is bigger, Bolt Biotherapeutics or Tvardi Therapeutics?

Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $13.22M compared with $12.80M for Bolt Biotherapeutics (BOLT).

Are Bolt Biotherapeutics and Tvardi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons